炎症生物标志物与卒中亚型:一个重要的新前沿
炎症是动脉粥样硬化斑块形成、生长和破裂的既定通路,也是冠心病和部分缺血性卒中发病机制的关键。抗炎治疗在冠心病患者中已证实获益,但在缺血性卒中患者中尚未证实。卒中病因异质性强,即使全面评估仍有高达30%-40%的患者病因不明,需明确卒中病因是否修饰炎症标志物与复发风险的关联,以改进抗炎药物随机试验的患者选择。
要点
- 炎症是动脉粥样硬化斑块形成、生长和破裂的既定通路,对冠心病和部分缺血性卒中发病至关重要。
- 抗炎治疗(如秋水仙碱和抗IL1β卡那奴单抗)在冠心病患者中获益已证实,在缺血性卒中患者中尚未证实。
- IL-6和高敏C反应蛋白(hs-CRP)与缺血性卒中后更高复发风险相关,但缺乏按卒中病因分层的体内 granular 结果。
核心结论
- 炎症是冠心病和部分缺血性卒中发病机制的关键通路,但抗炎治疗在缺血性卒中的获益尚未证实。
- 需明确卒中病因是否修饰炎症标志物与复发风险的关联,以改进抗炎药物随机试验的患者选择。
研究设计与样本
- 本文为综述/评论,未报告系统检索范围。
主要发现
- 炎症是动脉粥样硬化斑块形成、生长和破裂的既定通路。
- 抗炎治疗如秋水仙碱和抗IL1β卡那奴单抗在冠心病患者中获益已证实,在缺血性卒中患者中尚未证实。
- 即使全面评估,仍有高达30%-40%的患者卒中病因不明。
- 个体参与者数据Meta分析和孟德尔随机化研究均提示IL-6和高敏C反应蛋白(hs-CRP)与缺血性卒中后更高复发风险相关。
- 缺乏按卒中病因分层的体内 granular 结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation is an established pathway in the formation, growth, and rupture of atherosclerotic plaques. Inflammation is thus essential to the pathogenesis of coronary heart disease and some types of ischemic stroke.1 The benefit of anti-inflammatory therapies, such as colchicine2 and the anti-IL1β canakinumab,3 is proven in patients with coronary heart disease, yet it remains unproven for patients with ischemic stroke. Compared with coronary heart disease, the etiology of stroke is more heterogeneous. Besides arterio-arterial atherogenic embolism, possible etiologies are penetrator artery occlusion, cardioembolism, and other mechanisms. Finding a stroke etiology remains elusive in up to 30%-40% of patients despite a full evaluation. Understanding whether the stroke etiology modifies the association between inflammatory markers and recurrence risk is an important step to improve selection of patients for randomized trials on anti-inflammatory agents. IL-6 and high-sensitive CRP (hs-CRP) have been implicated in a higher recurrence risk after ischemic stroke by both an individual participant data meta-analysis4 and a Mendelian randomization study,5 but granular, in vivo results stratified by stroke etiology are lacking.
引用
- Chaturvedi S, De Marchis GM. Inflammatory Biomarkers and Stroke Subtype: An Important New Frontier. Neurology. 2023. PMID: 38165352. doi:10.1212/WNL.0000000000208098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。